What is Stoke Therapeutics, Inc.'s R&D?

Stoke Therapeutics, Inc. (STOK) reported R&D of $39.67M in Q1 2026.

How has Stoke Therapeutics, Inc.'s R&D changed year-over-year?

Stoke Therapeutics, Inc.'s R&D increased by 21.4% year-over-year, from $32.68M to $39.67M.

What is the long-term trend for Stoke Therapeutics, Inc.'s R&D?

Over 4 years (2021 to 2025), Stoke Therapeutics, Inc.'s R&D has grown at a 26.3% compound annual growth rate (CAGR), from $54.17M to $137.92M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Stoke Therapeutics, Inc. STOK R&D

R&D at other companies

Ionis PharmaceuticalsIONS

$228.9M+1.6%

Jazz PharmaceuticalsJAZZ

$196M+8.5%

Xenon PharmaceuticalsXENE

$88.51M+44.6%

Praxis Precision Medicines, Inc.PRAX

$77.99M+28.3%

Harmony Biosciences Holdings, Inc.HRMY

$69.38M+101%

Nurix Therapeutics, Inc.NRIX

$84.14M+20.8%

Other financials

Income statement

See full

Revenue$6.2M-96.1%

Operating income-$53.4M-148%

Net income-$50.0M-144%

EPS (diluted)-$0.79-142%

Balance sheet

See full

Cash & equivalents$155.7M-43.4%

Total debt$3.4M-42.5%

Total equity$394.9M+12.8%

Total assets$443.3M+8.9%

Cash flow

See full

Operating cash flow-$60.6M-146%

CapEx$353.0K+132%

Free cash flow-$60.9M-146%

Valuation

See full

Market cap$1.94B+436%

Enterprise value$1.79B+1,855%

P/S60.4×+58.5×

Profitability

See full

Operating margin-577.5%-597pp

Net margin-529.2%-556pp

FCF margin36.2%+18.4pp

Returns & leverage

See full

Return on equity-45.6%-66.1pp

Debt / equity0×0.0×

Current ratio9×+0.6×

Where this comes from

Reported directly by Stoke Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stoke Therapeutics, Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Stoke Therapeutics, Inc.'s R&D?: Stoke Therapeutics, Inc. (STOK) reported R&D of $39.67M in Q1 2026.
How has Stoke Therapeutics, Inc.'s R&D changed year-over-year?: Stoke Therapeutics, Inc.'s R&D increased by 21.4% year-over-year, from $32.68M to $39.67M.
What is the long-term trend for Stoke Therapeutics, Inc.'s R&D?: Over 4 years (2021 to 2025), Stoke Therapeutics, Inc.'s R&D has grown at a 26.3% compound annual growth rate (CAGR), from $54.17M to $137.92M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.